Given that PAU is highly comorbid with cardiometabolic disorders [73, 74], the observed effects may contribute to the cardioprotective properties of GIPR/GLP1R agonism, further supported by MR evidence linking reduced binge drinking to lower CAD risk. The gene discussed is GIPR; the disease is coronary artery disorder.